

## Supplementary information

### Molecular basis of HACD-TECR complex mediated very-long-chain fatty acid elongation reveal a potential target in colorectal cancer

Rui Lv<sup>1,2,#</sup>, Leiye Yu<sup>1,3,#</sup>, Jingyi Liu<sup>2,4,#</sup>, Youli Zhou<sup>5,6,#</sup>, Ruiping He<sup>1,#</sup>, Chen Wang<sup>1</sup>, Bing Gan<sup>1</sup>, Rujuan Ti<sup>7</sup>, Haizhan Jiao<sup>5</sup>, Baohui Song<sup>4</sup>, Yiqi Chen<sup>1</sup>, Feifei Lin<sup>8</sup>, Mei Gao<sup>6</sup>, Hongli Hu<sup>5</sup>, Shankai Yin<sup>3</sup>, Pinghong Zhou<sup>4</sup>, Lizhe Zhu<sup>7</sup>, Mingyan Cai<sup>4</sup>, Tian Xie<sup>9,\*</sup>, Jia Liu<sup>8,\*</sup>, Li Chen<sup>1,10,\*</sup>, Yunshi Zhong<sup>2,4,\*</sup>, Ruobing Ren<sup>1,2,\*</sup>

<sup>1</sup> Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China

<sup>2</sup> Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200020, China

<sup>3</sup> Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

<sup>4</sup> Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China

<sup>5</sup> Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China

<sup>6</sup> Central Research Laboratories, Chongqing General Hospital, Chongqing University & Chongqing Academy of Medical Sciences, 118 Xingguang Avenue, Liangjiang New Area, Chongqing 401147, China

<sup>7</sup> Warshel Institute of Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China

<sup>8</sup> China-Serbia "Belt and Road" Joint Laboratory for Natural Products and Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hitech Park, Shanghai 201203, China

<sup>9</sup> MOE Key Laboratory of Geriatric Diseases and Immunology, Biomedical Basic Research Center of Jiangsu, Institute of Molecular Enzymology, School of Life Sciences, Suzhou Medical College of Soochow University, Suzhou,

26 Jiangsu, 215123, China

27 <sup>10</sup> Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200438, China

28 # These authors contributed equally

29 \* To whom correspondence should be addressed. Email: [renruobing@fudan.edu.cn](mailto:renruobing@fudan.edu.cn)

30

## 31 **Supplementary methods**

### 32 **Bioinformatics**

33 For TECR expression analysis between human cancers and normal tissues, we conducted  
34 bioinformatics analysis on UCSC Xena (<https://xenabrowser.net/>). It is an online analysis tool for  
35 processing high-throughput RNA sequencing expression data of bulk tumorous and normal samples  
36 based on the Cancer Genome Atlas (TCGA) (<https://portal.gdc.cancer.gov/>), the Genotype-Tissue  
37 Expression (GTEx, <https://www.gtexportal.org/>) and Gene Expression Omnibus (GEO) (accession  
38 number GSE184093) databases. Log<sub>2</sub>-transformed FPKM values were used as normalized gene  
39 expression levels. Group differences were compared using the ggpubr R package, and statistical  
40 significance was assessed with Student's independent t-test. Graphs were constructed using GraphPad  
41 Prism (10.0, La Jolla, CA, USA) and R software.

42 The scRNA-seq dataset of colorectal cancer was retrieved from the Gene Expression Omnibus (GEO)  
43 database under accession number GSE132465. Data processing and downstream analyses were  
44 performed using the Seurat R package (version 5). To ensure consistency with the source studies, cell  
45 type annotations were adopted directly from the original metadata provided by the respective authors.  
46 The global cellular landscape was visualized using Uniform Manifold Approximation and Projection  
47 (UMAP) for dimensionality reduction. Furthermore, to investigate the role of TECR in tumor progression,  
48 its expression levels within the malignant epithelial cell subpopulation were specifically evaluated.  
49 Differential expression analysis was performed using the Wilcoxon rank-sum test, with statistical  
50 significance determined by adjusted P-values.

### 51 **Cell lines and culture protocols**

52 The HCT116, SW480, and SW620 cell lines were purchased from the Culture Collection of the Chinese  
53 Academy of Sciences, Shanghai, China (<http://www.cellbank.org.cn/>). The HEK293T cell line was  
54 obtained from the American Type Culture Collection (ATCC). The OVSAHO, and A2780S cell lines were  
55 kindly provided by Shengtao Zhou (Sichuan University). The ISHIKAWA cell line was a kind gift from  
56 Lingbo Wang. The LICCF, REB, and TFK-1 cell lines were gifts from Hongyang Wang (Fudan University).  
57 The MDA-MB-231, HuH7, and HeLa cell lines were gifts from Tongjin Zhao (Fudan University). The  
58 LICCF, REB, TFK-1 cells were cultured in RPMI-1640 medium (Macgene, CM10041) supplemented with  
59 10% (v/v) fetal bovine serum (Every green, 11011-8611). The other cell lines were cultured in DMEM  
60 medium (Macgene, CM10013) supplemented with 10% Fetal Bovine Serum (FBS) at 37°C in an  
61 atmosphere of 5% CO<sub>2</sub>.

## 62 **Generation of knockdown or knockout cell lines**

63 For the transient knockdown (KD) of TECR, the anti-TECR siRNA (siTECR1 or siTECR2) was directly  
64 transfected into the various cancer cell lines for cell proliferation assays. All transfections were  
65 performed using Lipofectamine™ 3000 Reagent (Invitrogen, L3000015) according to the manufacturer's  
66 instructions.

67 For the stable knockdown of TECR, the anti-TECR shRNA (shTECR1 or shTECR2) was inserted into  
68 the pLKO.1 plasmid and co-transfected with viral packaging plasmids (psPAX2 and pMD2.G) using PEI  
69 4000 (Polysciences, 24885-2) into HEK293T cells to generate and amplify lentivirus first. After  
70 transfection for 48 hours, the virus was collected from the culture medium and filtered through a 0.45 μ  
71 m filter. The HCT116 and SW480 cell lines were infected with the virus for 48 hours and then selected  
72 with 2 μg/mL puromycin for one week to generate the stable TECR-KD cell lines for further experiments.

73 For the stable knockout (KO) of TECR using the CRISPR-Cas9 system, the anti-TECR single-guide  
74 RNA (sgRNA) was cloned into the lentiCRISPR v2 plasmid and co-transfected with the same viral  
75 packaging plasmids into HEK293T cells to generate lentivirus similarly. The lentivirus was collected from  
76 the media after transfection for 48 hours. The HCT116 cells were infected with the lentivirus for 48 hours  
77 and selected with 2  $\mu\text{g/mL}$  puromycin for 4-5 weeks to generate monoclonal stable TECR-KO cell lines  
78 for further experiments.

### 79 **Cell proliferation assay**

80 Cell proliferation was evaluated using the Cell Counting Kit-8 (Yeasen Biotech, 40203ES80) based on  
81 the manual. Briefly, about  $1 \times 10^3$  cells were seeded in the 96-well plates with three replicates for each  
82 group. After cell attachment, the CCK-8 reagent was added at the indicated time points (1 day, 2 days,  
83 3 days, 4 days, and 5 days). Following incubation at 37°C for 1 hour, the absorbance at 450 nm was  
84 measured using a microplate reader to determine cell viability.

### 85 **Colony formation assays and crystal violet staining**

86 About  $1\sim 2 \times 10^3$  HCT116 or SW480 cells (control or TECR-KD cells) were seeded in the 6-well cell  
87 culture plates with the complete cell culture medium (DMEM with 10% FBS) and cultured for 10~14  
88 days. Then the cells were fixed with 4% paraformaldehyde in PBS for 10 minutes at room temperature  
89 and stained with 0.1% crystal violet staining (Servicebio; G1014) to assess the colony formation capacity  
90 of the cells.

### 91 **Invasion and migration assay**

92 Cell migration and invasion assays were conducted using transwell chambers with 8- $\mu\text{m}$  pore  
93 membranes (BIOFIL; TCS020024). For the migration assay,  $1 \times 10^5$  HCT116 or SW480 cells (control or

94 TECR-KD cells) were suspended in 200  $\mu$ L of serum-free DMEM medium and seeded into the upper  
95 chamber, while the lower chamber was filled with 700  $\mu$ L of DMEM medium containing 10% FBS as a  
96 chemoattractant. After incubation for 24~48 hours at 37°C, non-migrated cells remaining on the upper  
97 surface were gently removed with a cotton swab. The migrated cells on the lower surface of the  
98 membrane were fixed with 4% paraformaldehyde for 10 minutes, stained with 0.1% crystal violet for 10  
99 minutes, and imaged under a light microscope. For the invasion assay, the upper chambers were pre-  
100 coated with 50  $\mu$ L of Matrigel (Absin, abs9490; diluted 1:8 in serum-free DMEM) and incubated at 37°C  
101 for 1 hour before cell seeding. The subsequent steps were performed in the same manner as for the  
102 migration assay.

### 103 **Cell cycle assay**

104 The HCT116 cells (control or TECR-KD cells) grown in the logarithmic phase were stained using a PI  
105 Staining Kit (Solarbio; C0080). Briefly, the cells were incubated with a 20  $\mu$ g/mL staining solution for 20  
106 minutes at 37°C. After washing with PBS, cells were analyzed via flow cytometry within 30 minutes. All  
107 procedures were performed in the dark.

### 108 **Animal studies**

109 Male BALB/c nude mice (6 weeks old) were used for the subcutaneous xenograft tumor model. Briefly,  
110  $1 \times 10^6$  HCT116 cells (control or TECR-KD cells) suspended in 0.2 mL of PBS were subcutaneously  
111 injected into the flank of each mouse. Tumor growth was monitored every 2 days, and tumor volume  
112 was calculated using the formula: volume = (length  $\times$  width<sup>2</sup>) / 2. Mice were euthanized 14 days after  
113 cell injection, and the tumors were excised, photographed, and weighed for subsequent analysis. All  
114 animal experiments were approved by the Institutional Animal Care and Use Committee and performed

115 by institutional guidelines.

## 116 **Sample collections**

117 This study included 261 tissue samples in the colorectal tumor tissue microarray, comprising 87 matched  
118 pairs of normal intestinal mucosa, colorectal adenoma, and colorectal cancer tissues from 87 patients  
119 with colorectal cancer. All samples were collected from Zhongshan Hospital, Fudan University, Shanghai,  
120 between September 2020 and September 2022. All enrolled patients met the inclusion criteria of  
121 receiving no comprehensive treatment, including radiotherapy or chemotherapy, before sampling. The  
122 Ethics Committee of Zhongshan Hospital, Fudan University approved the study protocol. The  
123 pathological diagnosis of all tissue specimens was independently confirmed by two experienced  
124 pathologists.

## 125 **Immunohistochemistry (IHC)**

126 Immunohistochemical staining was performed on paraffin-embedded tissue microarrays (TMAs) derived  
127 from human colorectal cancer (CRC) specimens. The staining procedure was conducted using a  
128 commercial immunohistochemical detection kit (Zhongshan Jinqiao Biotechnology; SP-9000) following  
129 the manufacturer's protocol. The primary antibodies used in the experiments included anti-TECR  
130 primary antibody (1:200 dilution; Abcam; ab247124). For the TMAs, TECR expression levels were semi-  
131 quantitatively evaluated using the H-score method. The H-score was calculated using the formula: H-  
132 score =  $\sum (P_i \times i) = (\text{percentage of weakly stained cells} \times 1) + (\text{percentage of moderately stained cells} \times$   
133  $2) + (\text{percentage of strongly stained cells} \times 3)$ [1-3].

## 134 **Immunofluorescent staining**

135 The xenograft tumor tissues from nude mice were fixed in 4% paraformaldehyde for 24 hours at room

136 temperature, paraffin-embedded, and serially sectioned at 5  $\mu\text{m}$ . Sections were treated with 3%  $\text{H}_2\text{O}_2$   
137 and subjected to heat-induced antigen retrieval in citrate buffer (pH 6.0). Upon cooling to room  
138 temperature, nonspecific binding was blocked with 3% BSA. Sections were then incubated overnight at  
139  $4^\circ\text{C}$  with the primary antibody (1:500; Servicebio; GB111499). Following PBS washes, samples were  
140 stained with a fluorophore-conjugated secondary antibody (1:300; Servicebio; GB25303) and mounted  
141 with DAPI-containing medium.

### 142 **LC/MS analysis of fatty acids in cell extracts**

143 To analyze the total cellular fatty acids, a total of  $4 \times 10^6$  HCT116 cells (control or TECR-KO cells) were  
144 resuspended with 0.9 mL of an ice-cold methanol:isopropanol (MeOH:IPA, 1:1, v/v) mixture. The lipids  
145 were saponified by adding 0.1 mL 3 M KOH and heated at  $60^\circ\text{C}$  for 1 h, and the mixture was acidified  
146 by adding 0.1 mL formic acid after cooling down. The saponified fatty acids were extracted with hexane,  
147 dried down by  $\text{N}_2$  flow, and resuspended in methanol:isopropanol (MeOH:IPA, 1:1, v/v) mixture. Lipid  
148 extracts were analyzed using a Vanquish F UHPLC system (Thermo Fisher Scientific) coupled with a  
149 Thermo Orbitrap Exploris 480 mass spectrometer. Chromatographic separation was achieved on an  
150 Acclaim C30 column (3  $\mu\text{m}$ ,  $2.1 \times 150$  mm) maintained at  $45^\circ\text{C}$ . The mobile phase consisted of solvent  
151 A (10 mM ammonium formate with 0.1% formic acid in water:acetonitrile 40:60, v/v) and solvent B (10  
152 mM ammonium formate with 0.1% formic acid in isopropanol:acetonitrile 90:10, v/v). The flow rate was  
153 set to 0.26 mL/minute with a gradient elution program as follows: 0-2 minutes, 15% B; 3 minutes, 30%  
154 B; 10.5 minutes, 45% B; 14 minutes, 97% B; 14-18 minutes, hold at 97% B; 18-18.1 minutes, return to  
155 15% B; and 18.1-25 minutes, re-equilibration at 15% B. The injection volume was 10  $\mu\text{L}$ , and the  
156 autosampler was maintained at  $6^\circ\text{C}$ . Mass spectrometric analysis was performed in negative ion mode  
157 using full scan with a scan range of m/z 200–1500. The resolution was set to 240,000 at m/z 200.

## 158 **Co-IP experiment and peptide-competition assay**

159 For the co-immunoprecipitation (co-IP) experiment with His-tagged human HACD2 and Flag-tagged  
160 human TECR, the protein were co-expressed in Expi293 similarly as above. The cells were collected  
161 and resuspended in buffer C (25 mM HEPES pH 7.5, 150 mM NaCl, 2% glycerol). The cell lysis was  
162 extracted by 1% n-Dodecyl- $\beta$ -D-Maltopyranoside (DDM; Anatrace) and 0.1% CHS in the presence of  
163 protease inhibitors. After centrifugation, the supernatant was immunoprecipitated with Ni-NTA affinity  
164 resin. The resin was thoroughly washed with buffer C containing 25mM imidazole and 0.02% DDM and  
165 0.002% CHS. Bound proteins were subsequently eluted using buffer C supplemented with 0.02% DDM,  
166 0.002% CHS, and 250mM imidazole. The eluted samples were analyzed by Western blotting. For the  
167 co-immunoprecipitation (co-IP) experiment with C-terminal His-tagged *C. elegans* HACD and Flag-  
168 tagged *C. elegans* TECR, the codon-optimized HACD and TECR sequences were individually inserted  
169 into pMLink vector. The protein co-expression and co-IP experiments were performed similarly as above.

170 For the peptide-competition assay, the His-tagged human HACD2 and Flag-tagged human TECR were  
171 co-expressed in Expi293. After membrane extraction by 1% DDM and 0.1% CHS, the supernatant was  
172 incubated with anti-Flag G1 affinity resin. Following washing, the resin was incubated with various  
173 peptides at a concentration of 400 $\mu$ g/ml for 1 hour. Then the resin was washed and eluted with the 200  
174  $\mu$ g/mL Flag peptide for western blotting analysis.

## 175 **Molecular dynamics simulation**

176 The 3-hydroxyacyl-CoA substrate was docked into the protein by DSDP blind docking module[4]. The  
177 Membrane Builder module in CHARMM-GUI server[5] was used to prepare the molecular dynamics  
178 (MD) simulation inputs, including a membrane of pre-equilibrated (310 K) POPC lipids based on the

179 OPM database[6] alignment, TIP3P solvent with 0.15 M Na<sup>+</sup>/Cl<sup>-</sup> ions and the CHARMM36 force field[7].  
180 The force field of the ligand was generated by the CGenFF program[8]. Three independent 100-ns MD  
181 simulations were performed. All MD simulations were performed using GROMACS-2019.4[9]. The  
182 CHARMM36 force-field was used to describe the interactions in the system. Energy minimization was  
183 performed for 10000 steps by the steepest descent algorithm. Then a 100 ps NVT simulation was  
184 performed at 310 K for solvent equilibration, followed by a 1 ns NPT equilibration to 1 atm using the  
185 Berendsen barostat[10]. The production simulations were performed with a time-step of 2 fs using  
186 Parrinello-Rahman barostat[11]. In all constant temperature simulations, the Bussi (velocity-rescaling)  
187 thermostat was used[12]. Long-range electrostatic interactions were treated by the particle-mesh Ewald  
188 method[13]. The short-range electrostatic and van der Waals interactions both used a cutoff of 10 Å. All  
189 H-bonds were constrained by the LINCS algorithm[14].

190

## 191 **References**

- 192 1. Maclean, A., et al., *Fallopian tube epithelial cells express androgen receptor and have a*  
193 *distinct hormonal responsiveness when compared with endometrial epithelium*. Hum  
194 Reprod, 2020. **35**(9): p. 2097-2106.
- 195 2. Dogan, S., et al., *DNA methylation-based classification of sinonasal undifferentiated*  
196 *carcinoma*. Mod Pathol, 2019. **32**(10): p. 1447-1459.
- 197 3. Paschalis, A., et al., *Prostate-specific Membrane Antigen Heterogeneity and DNA Repair*  
198 *Defects in Prostate Cancer*. Eur Urol, 2019. **76**(4): p. 469-478.
- 199 4. Huang, Y., et al., *DSDP: A Blind Docking Strategy Accelerated by GPUs*. J Chem Inf  
200 Model, 2023. **63**(14): p. 4355-4363.
- 201 5. Jo, S., et al., *CHARMM-GUI: a web-based graphical user interface for CHARMM*. J  
202 Comput Chem, 2008. **29**(11): p. 1859-65.
- 203 6. Lomize, M.A., et al., *OPM database and PPM web server: resources for positioning of*  
204 *proteins in membranes*. Nucleic Acids Res, 2012. **40**(Database issue): p. D370-6.
- 205 7. Huang, J. and A.D. MacKerell, Jr., *CHARMM36 all-atom additive protein force field:*  
206 *validation based on comparison to NMR data*. J Comput Chem, 2013. **34**(25): p. 2135-  
207 45.
- 208 8. Vanommeslaeghe, K., et al., *CHARMM general force field: A force field for drug-like*

- 209            *molecules compatible with the CHARMM all-atom additive biological force fields.* J  
210            Comput Chem, 2010. **31**(4): p. 671-90.
- 211            9.        Abraham, M.J., et al., *GROMACS: High performance molecular simulations through*  
212            *multi-level parallelism from laptops to supercomputers.* SoftwareX, 2015. **1-2**: p. 19-25.
- 213            10.       Berendsen, H.J.C., et al., *Molecular dynamics with coupling to an external bath.* The  
214            Journal of Chemical Physics, 1984. **81**(8): p. 3684-3690.
- 215            11.       Parrinello, M. and A. Rahman, *Crystal Structure and Pair Potentials: A Molecular-*  
216            *Dynamics Study.* Physical Review Letters, 1980. **45**(14): p. 1196-1199.
- 217            12.       Bussi, G., D. Donadio, and M. Parrinello, *Canonical sampling through velocity rescaling.* J  
218            Chem Phys, 2007. **126**(1): p. 014101.
- 219            13.       Darden, T., D. York, and L. Pedersen, *Particle mesh Ewald: An  $N \cdot \log(N)$  method for Ewald*  
220            *sums in large systems.* The Journal of Chemical Physics, 1993. **98**(12): p. 10089-10092.
- 221            14.       Hess, B., et al., *LINCS: A linear constraint solver for molecular simulations.* Journal of  
222            Computational Chemistry, 1997. **18**(12): p. 1463-1472.

223


224



228 TECR transcription profiles in tumor samples and paired normal tissues. The position of each dot  
229 represents the amount of gene transcription level in the sample. **b-d**, UMAP representations of CRC  
230 single-cell sequencing dataset from GSE132465. TECR expression in CRC single-cell sequencing  
231 data between non-malignant cells and malignant cells from GSE132465. FPKM values were log2-  
232 transformed to normalize gene expression data. Significance was determined via an unpaired  
233 Student's t-test (a). Differential expression analysis was performed using the Wilcoxon rank-sum test,  
234 with statistical significance determined by adjusted P-values (d). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001,  
235 \*\*\*\*P < 0.0001.

236

237




238

239

**Fig. S2 | Cell proliferation analysis of various cancer cell lines upon TECR knockdown.**

240

241



242

243 **Fig. S3 | Cryo-EM analysis of the human HACD2-TECR complex. a**, Size-exclusion


244 chromatography (SEC) profile and Coomassie blue-stained SDS-PAGE gel of the purified human

245 HACD2-TECR complex. b, Representative cryo-EM image and 2D class averages of the HACD2-

246 TECR complex. c, Cryo-EM data processing flowchart of the HACD2-TECR complex datasets.

247

248



249

250 **Fig. S4 | Cryo-EM analysis of the crosslinked human HACD2-TECR complex.** a, SEC profile and

251 Coomassie blue-stained SDS-PAGE gel of the crosslinked human HACD2-TECR complex. b,

252 Representative cryo-EM image and 2D class averages of the crosslinked HACD2-TECR complex. c,

253 Cryo-EM data processing flowchart of the crosslinked HACD2-TECR complex dataset. d-e, Euler

254 angle distribution (**d**) and gold-standard FSC curves (**e**) of the crosslinked HACD2-TECR complex. **f**,

255 Cryo-EM map and structural model of the human HACD2-TECR complex. The structural models of


256 HACD2 and TECR predicted by AlphaFold were docked into the moderate-resolution 3D EM map.

257 HACD2 and TECR are colored purple and wheat, respectively.

258

259

260



261

262 **Fig. S5 | Cryo-EM analysis of the *C. elegans* HACD-TECR complex.** **a**, SEC profile and Coomassie

263 blue-stained SDS-PAGE gel of the *C. elegans* HACD-TECR complex. **b**, Representative cryo-EM

264 image and 2D class averages of the *C. elegans* HACD-TECR complex. **c**, Cryo-EM data processing  
265 flowchart of the *C. elegans* HACD-TECR complex. **d-f**, Euler angle distribution (**d**), gold-standard FSC  
266 curves (**e**), and local resolution map (**f**) of the *C. elegans* HACD-TECR complex. **g**, Representative  
267 density maps of the HACD and TECR subunits, contoured at  $5\sigma$ .  
268

CeHACD .....  
HsHACD2 .....  
HsHACD1 .....  
HsHACD3 MENQVLTPHVYWAQRHRELYLRVELSDVQNPAISITENVLHFKAQGHGAKGDNVYEFHLEFLDLV 65  
HsHACD4 .....  
PHS1 .....

HsHACD2 — — — — —

CeHACD .....  
HsHACD2 ..... MAAVAATAAAKNGGGGGRAGA 22  
HsHACD1 ..... MGRLTEAAAAGSGSRAAGWAGSPPTLLPLSPTSPRCAATMASSDEDDGTNGGASEAGE 57  
HsHACD3 KPPEVYKLTQRQVNIIVQKKVSVQWVERLTQKEKRPLFLAPDFDRWLDES DAEMELRAKEEERLNK 130  
HsHACD4 ..... MGPLALPAWLQPRYR..... 15  
PHS1 .....

CeHACD ———— TM1 ———— TM2 ————  
HsHACD2 ———— TM1 ———— TM2 ————

CeHACD ..... MSVQTYLVAYNVLIQILG..WSAILVKTIVLGLANGLTWPQLYE SVEFELKIFQ 50  
HsHACD2 GDASGTRKKKGGPLATAYLVVIYNVVMTAG..WLVIAVGLVVRAYLAKGSYHSLYY SIEKPLKFFQ 85  
HsHACD1 .DREAPGERRRRLGVLATAWLTIFYDIAMTAG..WLVLAIAMVRFYMEKGT HRGLYKSIQKTLKFFQ 119  
HsHACD3 LRLESEGS PETLTNLRKGYLFMYNLVQFLGFSWIFVNLTVRFCILGKESFYDTHFTVADMMYFCQ 195  
HsHACD4 .....KNAYLFIYLIQFCGHSWIFTNMTVRRFFSFGKDSMVDTFYAIIGLVMRLCQ 65  
PHS1 .....MSKKLASPLSEFLYLNLLSAGV..WSYLLYLIVISLYPKVGVQPAFFYQTKNVATLVQ 54

CeHACD ———— TM3 ———— LH1 ———— TM4 ————  
HsHACD2 ———— TM3 ———— TM4 ————

CeHACD TAAILEVIHAIIVGLVRSFVGT TAMQVTSRVVLVWPIILHLCSTAR..FSIGVPLLLVAWSVTEVIR 113  
HsHACD2 TGALLEILHCAIGIVPSSVVLTSFQVMSRVFLIWAIVTHSVKEVQ..SEDSVLLFVIAWTITEIIR 148  
HsHACD1 TFALLEIVHCLIGIVPTSVIVITGVQVSSRIFFMVWLITHSIKPIQ..NEESVVLFLVAWTVTEITR 182  
HsHACD3 MLAVVETINAAGVTTSPVLP SLIQLLGRNFILFIIFGTMEEMQ..NKAVVFFVFYLSAIEIFR 258  
HsHACD4 SVSLELLHIYVGIENHLLPRFLQLTERIIILFVVIITSQEEVQ..EKYVVCVLFFVFNLLDMVR 128  
PHS1 CGAIIIEIINSFLGVVRSPLLTIVAAQVSSRLLVVLGIFQLLPNTSGVQSVVYISLLLAWSITEIVR 119

CeHACD ———— TM5 ————  
HsHACD2 ———— TM5 ————

CeHACD YSFYALSVLKQP.IPYFLLYLRYTLEFVLYPMGVSGELTLFASLNEVDEKKIL TLEMPNRLNMG 177  
HsHACD2 YSFYTFSLLNH..LPYLTKWARYTLEIVLYPMGVSGELTLIYAALPFVQRAGLY SISLPNKYNFS 211  
HsHACD1 YSFYTFSLLDH..LPYFIKWARYNFFIILYPVGVAGELTLIYAALPHVKKGTGMFSIRLPNKNYVS 245  
HsHACD3 YSFYMLTCIDM..DWKVLTWLRYTLWIPLYPLGCLAEAVSVIQSIPIFNETGRFSFTLPYPVKIK 321  
HsHACD4 YTYSMLSVIGI..SYAVLTVLSQTLWMPIYPLCVLAEAFAIYQSLPYFESFG..TYSTKLPFDLS 189  
PHS1 YLYYFFMLVFKNGAPKILILLRYNLFWILYPTGVASELRIRIYCALN.....AAESQYS 172

CeHACD ———— TM6 ————  
HsHACD2 ———— TM6 ————

CeHACD TISFHWVVIITAAALSYIPGFPQLYFYMIGQRKKILGGGSKKKQ... 218  
HsHACD2 FDYYAFILIMISYIPIFPQLYFHMIIHQRRKILSHTEEHKKFE.. 254  
HsHACD1 EDYYFLLITMASYIPLFPQLYFHMLRQRRKVLHGEVIVEKDD.. 288  
HsHACD3 VRFSPFLQIYLIIMIFLGLYINERHLYKQRRRRYQKKKKIH... 362  
HsHACD4 IYEPYVVKIYLMMLFIGMYFTYSHLYSERRDILGIFPIKKKM.. 232  
PHS1 LLYKRIITAAALAYIPGFPMLFLHMVAQRKKVMKSLRSSFGKKLI 217

★ Catalytic residues      □ U-shaped TM5/6 loop of HACD  
▼ TECR interacting residues      ◆ Intra-loop interacting residues within the U-shaped loop

269  
270 **Fig. S6 | Sequence alignment of HACD homologs.** Secondary structural elements of *C. elegans*  
271 HACD and human HACD2 are indicated above the sequence alignment. TM: transmembrane helix;  
272 LH: luminal helix. The catalytic residues are indicated by orange stars, while the TECR binding  
273 residues are indicated by green triangles. The U-shaped TM5/6 loop of HACD crucial for TECR


274 binding is indicated by blue box. The intra-loop interacting residues within the U-shaped loop are  
275 indicated by gray diamonds. The UniProt IDs of the aligned sequences are as follows: CeHACD:  
276 O17040; HsHACD1: B0YJ81; HsHACD2: Q6Y1H2; HsHACD3: Q9P035; HsHACD4: Q5VWC8; PHS1:  
277 P40857. "Ce" for *C. elegans*; "Hs" for Homo sapiens.

278

279

280

281



282

283 **Fig. S7 | Sequence alignment of TEHR homologs.** Secondary structural elements of *C. elegans*

284 TEHR and human TEHR are indicated above the sequence alignment. Secondary structural elements


285 of human SRD5A2 are indicated below the sequence alignment. CH: cytosolic helix. The catalytic

286 residues of TEHR and SRD5A2 are indicated by orange and gray stars, respectively. The HACD-

287 binding residues on TEHR are indicated by green triangles. The UniProt IDs of the aligned sequences

288 are as follows: CeTEHR: Q9N5Y2; HsTEHR: Q9NZ01; HsSRD5A2: P31213.

289



290

291

**Fig. S8 | Structural comparisons between human HADC2-TECR complex and *C. elegans* HADC-**

292

**TECR complex. a**, Superimposition of human HADC2-TECR complex and *C. elegans* HADC-TECR


293

complex. **b-d**, Superimpositions of the HADC subunits (**b**), TECR transmembrane domains (**c**), and

294   TECR ubiquitin-like domains (**d**). **e**, Perpendicular views of the central cavities within human HACD2  
295   and TECR transmembrane domains facing the cytosolic side of membrane. **f**, Similar lateral clefts  
296   formed by human HACD2-TM3/6 and TECR-TM3/6. **g**, The human HACD2 TM5/6 luminal loop is in  
297   close contacts with the TM3/4 and TM5/6 luminal loops of TECR. **h**, SEC profile and Coomassie blue-  
298   stained SDS-PAGE gel of purified human HACD2 alone and TECR alone.

299

300



301

302

**Fig. S9 | Structural comparisons between TECR and SRD5A2. a,** Superimposition of *C. elegans*

303

TECR subunit with human SRD5A2. The NADP-dihydrofinasteride (NADP-DHF) bound SRD5A2 (PDB

304

7BW1) and NADPH-bound TECR are colored light grey and blue, respectively. **b,** Potential substrate

305

entry sites on SRD5A2 and TECR. Both SRD5A2 and TECR are presented in the same view with the

306

NADP(H) cofactors located in similar positions. The DHF moiety occupies the potential steroid

307

substrate binding site on SRD5A2. **c,** Superimposition of SRD5A2 and HACD-bound TECR. The TM1

308 of SRD5A2 is situated between the opposing lateral clefts formed by the TM3/6s of HACD and TECR.

309 **d**, Superimposition of the NADPH coordination residues in *C. elegans* TECR and SRD5A2. **e**,


310 Superimposition of the catalytic residues of *C. elegans* TECR subunit, human TECR subunit, and

311 SRD5A2.

312

313

314



315

316 **Fig. S10 | TECEC knockdown suppresses CRC cell proliferation and progression. a**, Cell cycle


317 arrest of TECEC-KD HCT116 cells. **b**, TECEC-KD suppresses CRC cell invasion and migration. **c**,

318 Representative images of Ki-67 immunofluorescence staining of xenograft tumors. Scales bar, 50 µm.

319 **d**, Quantification of Ki-67 staining of (c) (n = 9/group). Data are presented as mean ± SD. \*\*\*\*p <

320 0.0001 by Student's t test.

321



322

323 **Fig. S11 | Structural features of HACD. a**, Superimposition of *C. elegans* HACD subunit with human

324 ELOVL7. The acyl-CoA-bound ELOVL7 (PDB 6Y7F) are colored light grey and cyan. The acyl-CoA

325 substrate bound with ELOVL7 is shown in magenta sticks. The *C. elegans* HACD subunit is colored

326 green. **b**, HACD and ELOVL7 share similar central cavities formed by TM1-6 of HACD and TM2-7 of  
327 ELOVL7. **c**, The docked 3-hydroxyacyl-CoA substrate within CeHACD occupies a position roughly  
328 similar to that for acyl-CoA substrate in ELOVL7. **d**, The distances between Y142 or E149 in TM5 of  
329 CeHACD and the C-2 or C-3 positions of the 3-hydroxyacyl-CoA substrate throughout the 100 ns  
330 molecular dynamics (MD) simulation trajectory. Both Y142 and E149 remain in close proximity to the  
331 C-2 and C-3 positions of the 3-hydroxyacyl-CoA substrate throughout most of the simulation trajectory  
332 (from 18 ns to 70 ns). **e**, Proposed dehydration mechanism of human HACD2. The tyrosine is likely  
333 responsible for abstracting a proton from the C-2 position, and the glutamate residue may facilitate the  
334 elimination of the hydroxyl group at the C-3 position of 3-hydroxyacyl-CoA substrate. **f**, HACD exhibits  
335 an obvious shift and rotation towards TECR compared to ELOVL7. This movement is probably to  
336 facilitate transfer of product from HACD to TECR for catalysis coupling. The docked 3-hydroxyacyl-  
337 CoA substrate for HACD is shown in spheres.

338

339

340

341 **Table S1 | Cryo-EM data collection, refinement, and validation statistics.**

	<i>C. elegans</i> HACD-TECR (EMD-68536) (PDB 22OF)	Human HACD2-TECR (EMD-38493)
<b>Data collection and processing</b>		
Magnification	105,000	105,000
Voltage (kV)	300	300
Electron exposure (e <sup>-</sup> /Å <sup>2</sup> )	52.76	58.09
Defocus range (µm)	-1.5- -2.0	-1.0- -2.0
Pixel size (Å)	0.85	0.83
Symmetry imposed	C1	C1
Initial particle images (no.)	35,015,130	4,851,341
Final particle images (no.)	131,428	67,876
Map resolution (Å)	3.60	6.32
FSC threshold	0.143	0.143
Map resolution range (Å)	3.0-5.0	
<b>Refinement</b>		
Initial model used (PDB code)	AF2 model	
Model resolution (Å)	3.6/4.0	
FSC threshold	0.143/0.5	
Model composition		
Non-hydrogen atoms	4093	
Protein residues	515	
Ligands	1	
<i>B</i> factors (Å <sup>2</sup> )		
Protein	117.45	
Ligand	111.17	
R.m.s. deviations		
Bond lengths (Å)	0.004	
Bond angles (°)	0.729	
Validation		
MolProbity score	1.80	
Clashscore	10.33	
Poor rotamers (%)	0.00	
Ramachandran plot		
Favored (%)	96.09	
Allowed (%)	3.72	
Disallowed (%)	0.20	